BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet. 1997;350:1445-1446. [PMID: 9371171 DOI: 10.1016/s0140-6736(05)64206-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999;58 Suppl 1:I107-I113. [PMID: 10577986 DOI: 10.1136/ard.58.2008.i107] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 5.4] [Reference Citation Analysis]
2 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13:5979-5984. [PMID: 18023086 DOI: 10.3748/wjg.13.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
3 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-84. [PMID: 18023086 DOI: 10.3748/wjg.v13.45.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
4 Xie Y, Li D, Luan X, Jin S, Yan B, Tian F. Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells. Can J Gastroenterol Hepatol 2020;2020:8861854. [PMID: 32766176 DOI: 10.1155/2020/8861854] [Reference Citation Analysis]
5 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
7 Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961. [PMID: 14997189 DOI: 10.1038/sj.bjc.6601579] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
8 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
10 Bauditz J, Lochs H. Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13(45): 5979-5984 [DOI: 10.3748/wjg.v13.i45.5979] [Reference Citation Analysis]
11 Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812-817. [PMID: 10732751 DOI: 10.1054/bjoc.1999.1004] [Cited by in Crossref: 245] [Cited by in F6Publishing: 208] [Article Influence: 11.1] [Reference Citation Analysis]
12 Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892. [PMID: 9607928 DOI: 10.1084/jem.187.11.1885] [Cited by in Crossref: 406] [Cited by in F6Publishing: 380] [Article Influence: 16.9] [Reference Citation Analysis]
13 Li T, Qiu Y, Li X, Zhuang X, Huang S, Li M, Feng R, Chen B, He Y, Zeng Z, Chen M, Zhang S. Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Front Med (Lausanne) 2020;7:557986. [PMID: 33240902 DOI: 10.3389/fmed.2020.557986] [Reference Citation Analysis]
14 Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9. [PMID: 10189845 DOI: 10.1136/gut.43.2.203] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 3.3] [Reference Citation Analysis]
15 Tsai MJ, Chen C, Chen SH, Huang YT, Chiu TH. Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. J Gastroenterol 2011;46:822-33. [PMID: 21437599 DOI: 10.1007/s00535-011-0394-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]